A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma
N I Bohnen1, A Twijnstra, J Jolles
1Department of Neuropsychology and Psychobiology, University of Limburg, Maastricht, The Netherlands.
Abstract:
Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
More Related Videos
09:14Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025